Skip to main content
Premium Trial:

Request an Annual Quote

Tm Bioscience, Agilent Technologies, Rosetta Biosoftware, Qiagen

Premium

Tm Bioscience plans to roll out two new diagnostic tests: The Tag-It Mutation Detection Kits for P450-2C9, which will be launched at the end of the year; and the Tag-It Mutation Detection Kits for P450-2C19, which will roll out in the first half of next year and will be used to identify the presence or absence of mutations common in patients with atypical drug metabolism.


Agilent Technologies and Rosetta Biosoftware have introduced the Rosetta Luminator system version 2.0, a client-server bioinformatics system for storing and analyzing microarray data.

The Rosetta Luminator system, which was designed for small to mid-size commercial or academic gene-expression labs, was developed by Rosetta Biosoftware and will be distributed exclusively by Agilent as part of its broader gene-expression product line.

Version 2.0 will contain Analysis of Variance Study variations between different experiments using advanced patent-pending transformation algorithms that increase the sensitivity and specificity of analysis results; Bayesian classifiers to characterize unknown data; and Principal Component Analysis to determine the genes or experiments contributing most significantly to the variation within the data set and reduce the dimensionality of the data when clustering large data sets for greater performance.


Qiagen has launched its 4-for-Silencing siRNA duplexes. Qiagen claims that the products, which comprise a quartet of siRNA duplexes, will ensure that “at least one duplex will provide at least 70 percent knockdown” of gene expression. Qiagen will provide gratis full-sequence information when the siRNAs are delivered. Researchers are required to provide information about their target gene in most formats, though RefSeq entries are preferred, the company said.

 

Filed under

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.